top of page
Search

Guidance on the Licensing of Biosimilar Products - United Kingdom (MHRA)

Writer's picture: Sharan MuruganSharan Murugan
May 8, 20211 min read

Updated: Aug 21, 2021

What is a Biosimilar Medicine?

Biosimilar medicine is a biological medicine that is developed to be highly similar and clinically equivalent (in terms of quality, safety and efficacy) to an existing biological medicine that has already been authorised in the European Union, (known as the reference biological medicine or originator medicine).


Biosimilar medicines should be considered to be therapeutically equivalent to the reference medicine within their authorised indications.


The purpose of this guideline is to provide developers of similar biological medicinal products (also known as biosimilars) with a clear outline of the requirements for biosimilar products in Northern Ireland/Great Britain/UK.


The guidance is effective from 6 May 2021.

Comments

I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page